CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-30 | LEONARD JOHN M President and CEO | Sale | −2,598 | $159.18 | $414K | 720,246 |
| 2021-08-30 | LEONARD JOHN M President and CEO | Sale | −725 | $159.98 | $116K | 719,521 |
| 2021-08-30 | LEONARD JOHN M President and CEO | Sale | −216 | $160.69 | $35K | 719,305 |
| 2021-08-30 | LEONARD JOHN M President and CEO | Option exercise · Stock Option (right to buy) | −11,637 | 212,501 | ||
| 2021-08-30 | LEONARD JOHN M President and CEO | Option exercise · Stock Option (right to buy) | −27,167 | 127,833 | ||
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +27,000 | $13.40 | $362K | 29,391 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +70,000 | $14.25 | $998K | 99,391 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −15,839 | $152.75 | $2.4M | 83,552 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −20,645 | $153.64 | $3.2M | 62,907 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −28,669 | $154.77 | $4.4M | 34,238 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −16,115 | $155.61 | $2.5M | 18,123 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −7,425 | $156.79 | $1.2M | 10,698 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −3,932 | $157.77 | $620K | 6,766 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −1,515 | $158.90 | $241K | 5,251 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −2,653 | $159.64 | $424K | 2,598 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −207 | $160.47 | $33K | 2,391 |
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −27,000 | 82,000 | ||
| 2021-08-30 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −70,000 | 80,000 | ||
| 2021-08-30 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +2,400 | $12.62 | $30K | 3,191 |
| 2021-08-30 | Lebwohl David EVP, Chief Medical Officer | Sale | −200 | $155.43 | $31K | 2,991 |
Page 17 of 40 · 783 trades